KINDERHOOK, NY/ ACCESSWIRE / October 7, 2020 / American Bio Medica Corporation (OTC PINK: ABMC) announced that it has signed a distribution agreement with Co-Diagnostics, Inc. (CODX) which grants ABMC the right to market and sell Covid-19 Logix Smart Tests in the United States in a non-exclusive way.
Verification works through a one-step RT-PCR procedure in decreasing respiratory fluid samples, such as bronchoalveolar washing, sputum, tracheal suction, and samples of upper respiratory fluid, such as nasopharyngeal and oropharyngeal samples, received from patients with symptoms and symptoms. For Covid- 19, with easy-to-interpret effects in less than two hours.
ABMC will market Covid-19 diagnostic verification to qualified clinical laboratories under the Clinical Laboratory Improvement Amendments (CLIA), and in accordance with emergency use authorization issued to Co-Diagnostics, Inc. Usa. But it’s not the first time Food and Drug Administration on April 3, 2020.
Executive Director Melissa A. Waterhouse said: “We are excited to offer our consumers a verification solution for Covid-19. RT-PCR co-diagnostic verification allows us to offer our consumers a diagnostic tool that can be run on high -Speed machines. We can get a lot of desired data from antibody controls over time and we believe there are a number of additional programs for antibody control, however, the need for diagnostic controls remains wonderful in the United States. -PCR testing is a perfect complement to the immediate testing of IgG/IgM antibodies that we are already distributing. “
About American Bio Medica Corporation
American Bio Medica Corporation manufactures and markets accurate and cost-effective immunossai kits, primarily at the point of abuse drug collection, and distributes an immediate Covid-19 antibody screening test and RT-PCR to detect Covid-19. The company also recently conducts (by contract) s to breathe syncytial viruses (RSVs) and malaria and, with the ability to manufacture s for many other medical conditions, viruses and diseases at its FDA-registered and ISO-certified facilities.
This press release may include forward-looking statements. These forward-looking statements involve dangers and uncertainties that may also cause actual effects to vary, and those differences may also be simply material. These dangers and uncertainties include, but are not limited to, dangers and uncertainties related to the following: continued acceptance of our products, higher degrees of festivals in our industry, acceptance of new products, long-term sales, and degrees of profit to be tested. Rapid Antibody and RT-PCR Test for Covid-19 that we distribute, product development, compliance with regulatory needs including, but not limited to, our ability to download market approval for our product for our expected markets, asset rights of high level, our reliance on key personnel, outside sales and suppliers, our non-unusual inventory trading would possibly be subject to penny inventory rules, our history of net losses, recurring problems, and our ability to continue operating. The Company cannot be guaranteed to be successful in addressing those dangers and uncertainties and the Company assumes no legal responsibility to update any forward-looking statements based on actual effects. Investors are strongly encouraged to refer to the segment titled “Risk Factors” in the Company’s annual report on Form 10-K for the year ended December 31, 2019, the quarterly reports on Form 10-Q and other periodic reports. filed with the Securities and Exchange Commission for a discussion of the dangers and uncertainties that may also affect the effects of operations and the market value of the Company’s non-unusual shares.
Contacts:
SOURCE: American Bio Medica Corporation